Welcome to the AGAMENON-HER2 calculator website for advanced HER2+ gastric cancer!

We have developed the AGAMENON-HER2 prognostic tool to stratify HER2-positive gastric cancer patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints. This nomogram may be useful in stratifying HER2-positive tumours in future trials. In addition, it could be a valuable tool for making treatment decisions in daily clinical practice.

The calculator is only valid for patients with certain eligibility criteria, so please refer to the instructions. While this model offers an overview, bear in mind that a minority of your patients may have unusual predictive factors, which could affect how their quality of life evolves. External validation of the model is needed.

Predictions are merely approximate, so decisions should be made at the discretion of the attending physician.